4
Changes in Ownership
Summit Therapeutics Inc. Filed Acc 0001193805-20-001473
Chief Scientific Officer sold 30,431 shares at an average $4.30 ($130,770)
- Chief Scientific Officer acquired 30,431 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Powell David Jonathan · Chief Scientific Officer
Table I: Non-derivative
6 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2020-11-23 | Exercise or conversion : show line 1 in the form | +6,987 | $1.92 | $13,415 | 6,987 | D |
| 2020-11-23 | Sale : show line 2 in the form | −6,987 | $4.40 | $30,743 | 0 | D |
| 2020-11-24 | Exercise or conversion : show line 3 in the form | +11,374 | $1.92 | $21,838 | 11,374 | D |
| 2020-11-24 | Sale : show line 4 in the form | −11,374 | $4.21 | $47,885 | 0 | D |
| 2020-11-25 | Exercise or conversion : show line 5 in the form | +12,070 | $1.92 | $23,174 | 12,070 | D |
| 2020-11-25 | Sale : show line 6 in the form | −12,070 | $4.32 | $52,142 | 0 | D |
| Open-market sales · 30,431 sh · avg $4.30 · $130,770 | ||||||
Table II: Derivative
3 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2020-11-23 | Option exercise : show line 7 in the form Stock Option (right to buy) | −6,987 | $1.92 | $13,415 | 457,699 | D |
| 2020-11-24 | Option exercise : show line 8 in the form Stock Option (right to buy) | −11,374 | $1.92 | $21,838 | 446,325 | D |
| 2020-11-25 | Option exercise : show line 9 in the form Stock Option (right to buy) | −12,070 | $1.92 | $23,174 | 434,255 | D |
Loading xslF345X03/e620105_4-powell.xml…